Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 4/20 | 0.49 |
| ▸ | THRA | P10827 | 3/20 | 0.49 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | NPBWR1 | P48145 | 10/20 | 0.46 |
| ▸ | BCHE | P06276 | 3/20 | 0.44 |
| ▸ | ACHE | P22303 | 3/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4008223 | 0.83 | THRB (0.63) | THRBTHRARORCNPBWR1BCHE | |
| SCHEMBL7937662 | 0.79 | PCNA (0.47) | THRBTHRALTA4H | |
| SCHEMBL4008689 | 0.79 | THRB (0.46) | THRBTHRARORCNPBWR1BCHE | |
| SCHEMBL17087154 | 0.78 | NPBWR1 (0.52) | NPBWR1ACHEMCHR1LTA4H | |
| SCHEMBL12312518 | 0.78 | THRB (0.58) | THRBTHRARORCNPBWR1TAS1R3 | |
| SCHEMBL6374646 | 0.77 | TUBB1 (0.57) | THRBTHRARORC | |
| SCHEMBL23663172 | 0.77 | TAS1R3 (0.45) | THRBNPBWR1BCHEACHEMCHR1 | |
| SCHEMBL3228597 | 0.77 | TDP1 (0.50) | NPBWR1BCHEACHEMCHR1LTA4H | |
| SCHEMBL23663156 | 0.77 | NPBWR1 (0.48) | THRBTHRANPBWR1MCHR1LTA4H | |
| SCHEMBL6367633 | 0.76 | THRB (0.50) | THRBTHRARORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960604-B2 | Thyroid receptor ligands | PFIZER INC. (US) | 2005-11-01 | — | — | US | disclosed |
| US-20040110951-A1 | Thyroid receptor ligands | CHIANG YUAN-CHING P (US) | 2004-06-10 | — | — | US | disclosed |
| US-6620830-B2 | Certain thiazolidinedione, oxadiazolidinedione, and triazolone compounds which are thyroid receptor ligands | PFIZER, INC. | 2003-09-16 | — | — | US | disclosed |
| US-20010051645-A1 | Thyroid receptor ligands | CHIANG YUAN-CHING P (US) | 2001-12-13 | — | — | US | disclosed |
| EP-1148054-A1 | Thyroid receptor ligands | Pfizer Products Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051645-A1 | Thyroid receptor ligands | TSHR, THRB, THRA | THRB 2/4885THRA 3/4885RORC 302/4885 |
| US-20040110951-A1 | Thyroid receptor ligands | TSHR, THRB, THRA | THRB 2/4885THRA 3/4885RORC 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.